知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.082 秒)

    PEGYLATED TISSUE KALLIKREIN, AND PREPARATION METHOD THEREFOR AND USES THEREOF
    1.
    发明申请
    PEGYLATED TISSUE KALLIKREIN, AND PREPARATION METHOD THEREFOR AND USES THEREOF 审中-公开
    聚乙烯吡唑啉酮组合物及其制备方法及用途

    公开(公告)号：US20170049864A1

    公开(公告)日：2017-02-23

    申请号：US15109364

    申请日：2014-01-09

    申请人： ZONHON BIOPHARMA INSTITUTE INC. ,  GENSUN INSTITUTE OF BIOMEDICINE CO.,LTD.

    发明人： Bruce Yong MA ,  Jun WANG ,  Jing QIU ,  Dinglong WU ,  Chunlin XU ,  Chen CHEN ,  Yaofang WANG

    IPC分类号： A61K38/48 ,  C12N9/64 ,  A61K47/48

    CPC分类号： A61K38/4853 ,  A61K47/60 ,  C12N9/6445 ,  C12Y304/21035

    摘要： The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.

    摘要翻译： 本发明涉及聚乙二醇（PEG）改性蛋白质药物和聚乙二醇化组织激肽释放酶，其制备方法和用途被公开。 组织激肽释放酶具有SEQ ID No.1或SEQ ID No.2所示的序列，组织激肽释放酶可以是天然的或重组的。 PEG具有20至40kDa的分子量，并且与组织激肽释放酶的N-末端的初级氨基缀合。 除了显着延长半衰期，免疫原性显着降低和结构稳定均匀的优点外，本发明提供的聚乙二醇化KLK1的生物活性也提高到更高程度，这在治疗脑中风中更为显着 特别是糖尿病肾病。

    COMPOSITIONS AND METHODS FOR TREATING DIABETES
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING DIABETES 审中-公开
    用于治疗糖尿病的组合物和方法

    公开(公告)号：US20140134152A1

    公开(公告)日：2014-05-15

    申请号：US14116115

    申请日：2012-05-04

    申请人： Mark S Willimas ,  Matthew L. Charles

    发明人： Mark S Willimas ,  Matthew L. Charles

    IPC分类号： A61K38/48

    CPC分类号： A61K38/4853 ,  A61K38/482

    摘要： Embodiments of the present invention relate to compositions and methods of treating patients for type 1 diabetes mellitus (T1D) by administering a therapeutically effective dose of recombinant human KLK1, variants of KLK1, or active fragments thereof. Such patients may be increase risk patients for developing T1D or T1D patients in the Honeymoon Phase. Such treatment may be expected to prevent or delay the onset of T1D, to ameliorate the symptoms of T1D, or to ameliorate the extent to which the T1D manifests.

    摘要翻译： 本发明的实施方案涉及通过施用治疗有效剂量的重组人KLK1，KLK1的变体或其活性片段来治疗1型糖尿病（T1D）患者的组合物和方法。 这些患者可能会增加患者在蜜月期发展T1D或T1D患者的风险。 预期这种治疗可以预防或延缓T1D的发作，改善T1D的症状，或改善T1D表现的程度。

    Methods for modulating resistance to apoptosis using KLK6
    4.
    发明授权
    Methods for modulating resistance to apoptosis using KLK6 有权
    使用KLK6调节抗细胞凋亡的方法

    公开(公告)号：US08530427B2

    公开(公告)日：2013-09-10

    申请号：US13250599

    申请日：2011-09-30

    申请人： Isobel A. Scarisbrick

    发明人： Isobel A. Scarisbrick

    IPC分类号： A61K38/43

    CPC分类号： A61K39/39558 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/4853 ,  C12N9/6445 ,  C12Y304/21008

    摘要： This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.

    摘要翻译： 本文件提供了调节细胞抗凋亡能力的方法和材料。 例如，提供了用于将细胞暴露于KLK6多肽或增加的KLK6多肽活性的方法和材料，以促进对凋亡的抗性。 此外，提供了用于降低KLK6多肽促进细胞凋亡抗性的能力的方法和材料。

    ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    6.
    发明申请
    ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME 有权
    因子XA抑制剂的抗体及其使用方法

    公开(公告)号：US20130129693A1

    公开(公告)日：2013-05-23

    申请号：US13591098

    申请日：2012-08-21

    申请人： Uma Sinha ,  Genmin Lu ,  Pamela B. Conley

    发明人： Uma Sinha ,  Genmin Lu ,  Pamela B. Conley

    IPC分类号： C07K14/745

    CPC分类号： C12N9/6432 ,  A61K38/482 ,  A61K38/4826 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/4853 ,  A61K39/00 ,  A61K47/60 ,  C12Y304/21006

    摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

    摘要翻译： 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子X和因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开的是使用因子Xa抑制剂正在进行抗凝治疗的患者中的抗凝，停止或预防出血的方法。

    METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS
    7.
    发明申请
    METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS 审中-公开
    诊断和治疗代谢障碍的方法

    公开(公告)号：US20100008899A1

    公开(公告)日：2010-01-14

    申请号：US12374872

    申请日：2007-07-26

    申请人： Mark Williams

    发明人： Mark Williams

    IPC分类号： A61K38/48 ,  C12Q1/37 ,  A61P3/00

    CPC分类号： A61K38/4853 ,  A61K38/26 ,  A61K38/556 ,  A61K45/06 ,  C12Q1/37 ,  C12Y304/21035 ,  G01N2333/96455 ,  G01N2800/042 ,  A61K2300/00

    摘要： The invention relates to pharmaceutical compositions comprising tissue kallikrem (TK), and optionally a diabetes drug, a method of screening for a metabolic disorder by determining the concentration of TK and insulin in a biological sample from a test subject, a method of screening for a therapeutic agent for the treatment or prevention of a metabolic disorder, and a method for treating or preventing a metabolic disorder using a pharmaceutical composition comprising TK.

    摘要翻译： 本发明涉及包含组织激肽（TK）和任选的糖尿病药物的药物组合物，通过测定来自测试对象的生物样品中的TK和胰岛素的浓度来筛选代谢紊乱的方法，筛选 用于治疗或预防代谢紊乱的治疗剂，以及使用包含TK的药物组合物治疗或预防代谢紊乱的方法。

    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
    9.
    发明申请
    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers 审中-公开
    使用癌症标记物抑制内皮细胞增殖和调节血管生成的组合物和方法

    公开(公告)号：US20030012792A1

    公开(公告)日：2003-01-16

    申请号：US10131241

    申请日：2002-04-25

    发明人： John W. Holaday ,  Anne H. Fortier

    IPC分类号： A61K039/00

    CPC分类号： A61K38/4853 ,  A61K2300/00

    摘要： Compositions and methods for regulating angiogenesis wherein the compositions comprise cancer markers are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, the use of a cancer marker, such as PSA, CEA, HCG, NSE, or CA19-9, to inhibit or ameliorate angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy is disclosed.

    摘要翻译： 提供了用于调节血管生成的组合物和方法，其中组合物包含癌症标志物。 丝氨酸蛋白酶和激肽释放酶对人和其他动物细胞，特别是内皮细胞表现出有力的抗​​血管生成活性。 更具体地，公开了使用诸如PSA，CEA，HCG，NSE或CA19-9之类的癌症标志物抑制或改善血管生成和血管生成相关疾病如癌症，关节炎，黄斑变性和糖尿病性视网膜病变。

    Method of treating cancer
    10.
    发明申请
    Method of treating cancer 审中-公开
    癌症治疗方法

    公开(公告)号：US20020041880A1

    公开(公告)日：2002-04-11

    申请号：US09896251

    申请日：2001-06-29

    发明人： Deborah DeFeo-Jones ,  David C. Heimbrook ,  Raymond E. Jones

    IPC分类号： A61K039/00 ,  A61K038/14 ,  A61K038/08

    CPC分类号： A61K38/4853 ,  A61K47/65 ,  A61K2300/00

    摘要： The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis. The invention also relates to methods of preparing such compositions.

    摘要翻译： 本发明涉及使用PSA缀合物的化合物和作为血管生成抑制剂的化合物的组合来治疗癌症的方法，所述方法包括以任何顺序依次或同时向所述哺乳动物施用至少 选自由PSA缀合物的化合物和作为血管生成抑制剂的化合物组成的组中的两种治疗剂。 本发明还涉及制备这种组合物的方法。